ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 222 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $229,083 | -95.2% | 4,739 | -95.7% | 0.00% | -100.0% |
| Q3 2022 | $4,788,000 | +63.6% | 111,336 | +176.1% | 0.00% | +100.0% |
| Q1 2022 | $2,927,000 | +4.7% | 40,319 | +22.7% | 0.00% | 0.0% |
| Q4 2021 | $2,795,000 | -3.4% | 32,850 | -1.2% | 0.00% | 0.0% |
| Q3 2021 | $2,892,000 | -8.6% | 33,259 | +1.6% | 0.00% | -50.0% |
| Q2 2021 | $3,164,000 | +632.4% | 32,739 | +706.2% | 0.00% | – |
| Q1 2021 | $432,000 | -72.2% | 4,061 | -62.9% | 0.00% | -100.0% |
| Q4 2020 | $1,552,000 | +344.7% | 10,950 | +178.8% | 0.00% | – |
| Q3 2020 | $349,000 | -31.4% | 3,928 | -32.2% | 0.00% | – |
| Q2 2020 | $509,000 | +1442.4% | 5,790 | +773.3% | 0.00% | – |
| Q1 2020 | $33,000 | -89.1% | 663 | -90.6% | 0.00% | – |
| Q4 2019 | $302,000 | +37.3% | 7,059 | +37.0% | 0.00% | – |
| Q3 2019 | $220,000 | -30.8% | 5,153 | +2.8% | 0.00% | – |
| Q2 2019 | $318,000 | +715.4% | 5,014 | +795.4% | 0.00% | – |
| Q1 2019 | $39,000 | -17.0% | 560 | -48.1% | 0.00% | – |
| Q4 2018 | $47,000 | +14.6% | 1,079 | +100.9% | 0.00% | – |
| Q3 2018 | $41,000 | -4.7% | 537 | -2.2% | 0.00% | – |
| Q2 2018 | $43,000 | +290.9% | 549 | +155.3% | 0.00% | – |
| Q1 2018 | $11,000 | -54.2% | 215 | -59.0% | 0.00% | – |
| Q4 2017 | $24,000 | +33.3% | 525 | +51.7% | 0.00% | – |
| Q3 2017 | $18,000 | -96.9% | 346 | -96.3% | 0.00% | -100.0% |
| Q2 2017 | $584,000 | -91.5% | 9,395 | -90.8% | 0.00% | -85.7% |
| Q1 2017 | $6,887,000 | +7726.1% | 101,603 | +8939.4% | 0.01% | – |
| Q4 2016 | $88,000 | +203.4% | 1,124 | +171.5% | 0.00% | – |
| Q3 2016 | $29,000 | +107.1% | 414 | +47.3% | 0.00% | – |
| Q2 2016 | $14,000 | -66.7% | 281 | -56.5% | 0.00% | – |
| Q1 2016 | $42,000 | -51.7% | 646 | -17.4% | 0.00% | – |
| Q4 2015 | $87,000 | +45.0% | 782 | +25.9% | 0.00% | – |
| Q3 2015 | $60,000 | +275.0% | 621 | +288.1% | 0.00% | – |
| Q2 2015 | $16,000 | +100.0% | 160 | -5.9% | 0.00% | – |
| Q2 2014 | $8,000 | – | 170 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |